Advertisement BD Diagnostics, Lab21 in Aspergillus diagnostic assay development agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BD Diagnostics, Lab21 in Aspergillus diagnostic assay development agreement

BD Diagnostics has entered into a collaboration agreement with Lab21 to develop molecular diagnostic assay to detect the Aspergillus fungus.

Upon the development, Aspergillus fungus will be detected using BD MAX Molecular Testing System.

Lab21 CEO Graham Mullis said the potential to detect Aspergillus in blood using real-time polymerase chain reaction aids clinicians to accurately diagnose and screen the early and definitive detection of aspergillosis.

BD Diagnostics Diagnostic Systems president Tom Polen said BD plans to bring new assays to the BD MAX System in a broad range of disease categories.